CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.
  
  LEARNING OBJECTIVES

  • Appreciate the similarities and differences among commercially available and investigational chimeric antigen receptor (CAR) T-cell products for patients with hematologic cancers.
  • Recognize available efficacy and safety data with the use of CAR T-cell therapies directed at CD19, and effectively integrate this novel strategy into the treatment of relapsed/refractory (R/R) B-cell lymphomas.
  • Consider the recent FDA approval of the anti-CD19 CAR T-cell therapy brexucabtagene autoleucel for R/R mantle cell lymphoma, and identify patients for whom treatment with this agent might be beneficial.
  • Discuss the recent FDA approval of lisocabtagene maraleucel, a CAR T-cell therapy targeting CD19, for patients with R/R large B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and Grade IIIB follicular lymphoma (FL).
  • Appreciate available research findings supporting the recent FDA approval of the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel for patients with R/R FL.
  • Appraise the scientific rationale for and available data with CAR T-cell therapy directed at the B-cell maturation antigen (BCMA) in the care of patients with multiple myeloma (MM), and assess the similarities and differences among the various investigational approaches.
  • Recognize the recent FDA approval of the anti-BCMA CAR T-cell therapy idecabtagene vicleucel for R/R MM, and use this knowledge to identify patients who may be appropriate for a clinical trial of this approach.
  • Identify common adverse events associated with FDA-approved and investigational CAR T-cell therapies, and implement strategies to educate patients and manage complications.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Caron Jacobson, MD
  Assistant Professor of Medicine
  Harvard Medical School
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, bluebird bio, Bristol-Myers Squibb Company, Celgene Corporation, Kite, A Gilead Company, Lonza, Novartis, Precision BioSciences; Contracted Research: Kite, A Gilead Company, Pfizer Inc, Precision BioSciences.
  
  David G Maloney, MD, PhD
  Professor, Clinical Research Division
  Medical Director, Cellular Immunotherapy
  Leonard and Norma Klorfine Endowed Chair for Clinical Research
  Fred Hutchinson Cancer Research Center
  Professor of Medicine, Division of Oncology
  University of Washington
  Medical Director
  Cellular Immunotherapy and Bezos Family Immunotherapy Clinic
  Seattle Cancer Care Alliance
  Seattle, Washington
  
  Advisory Committee: A2 Biotherapeutics; Consulting Agreements: Amgen Inc, BioLineRx, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Legend Biotech, MorphoSys, Novartis, Umoja Biopharma; Contracted Research: Celgene Corporation, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company; Data and Safety Monitoring Board/Committee: BioLineRx; Rights to Royalties: Fred Hutchinson Cancer Research Center for patents licensed to Juno Therapeutics, a Celgene Company; Stock Options: A2 Biotherapeutics.
  
  Nikhil C Munshi, MD
  Kraft Family Chair
  Director of Basic and Correlative Science
  Jerome Lipper Multiple Myeloma Center
  Professor of Medicine
  Harvard Medical School
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Bristol-Myers Squibb Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
  
  Release date: August 2021
  Expiration date: August 2022